Ferric carboxymaltose can be safely administered at doses of 500 mg in hemodialysis patients, according to a new study.
Investigators analyzed retinal hemorrhages and macular edema events in patients treated with roxadustat or darbepoetin alfa.
Red blood cell transfusions can treat anemia over the short term but may increase the risk for adverse events, particularly those associated with blood volume, according to investigators.
In both dialysis and nondialysis trials, no increases in roxadustat dose were needed for inflamed patients.
In pooled analyses, researchers found no higher rates of major adverse cardiovascular events with roxadustat treatment among patients with anemia of dialysis- or nondialysis-dependent chronic kidney disease.
At 18-24 weeks, average hemoglobin levels in the roxadustat group was within target range.
In the prospective CKD-DOPPS study, only 40% for patients with hemoglobin less than 10 g/dL initiated anemia medication.
In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders.
A current meta-analysis of HIF-PHIs showed that these drugs improve the response rate of hemoglobin and decrease hepcidin levels.
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.